Skye Bioscience Inc

Skye Bioscience faces eight lawsuits alleging securities fraud, threatening investor confidence, stock value, and Nasdaq listing – is the biotech’s future at risk?

Skye Bioscience’s 2025 class‑action lawsuits target investors who bought shares Nov‑Oct 2025, with key law firms urging counsel before Jan 16 2026.

Skye Bioscience Inc.’s stock price is currently at $2.87, with a market capitalization of $66.3 million, but faces challenges with a negative price-to-earnings ratio.

Skye Bioscience Inc. is navigating significant market volatility as it prepares to release its Q1 earnings report, which will be crucial in determining the company’s trajectory and ability to capitalize on opportunities in the healthcare sector.